Private Advisor Group LLC increased its stake in shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) by 21.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 141,132 shares of the biotechnology company’s stock after buying an additional 24,966 shares during the period. Private Advisor Group LLC’s holdings in ZIOPHARM Oncology were worth $264,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in ZIOPHARM Oncology by 57.2% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 47,069 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 17,130 shares during the last quarter. Gamble Jones Investment Counsel acquired a new position in shares of ZIOPHARM Oncology in the fourth quarter valued at approximately $56,000. SG Americas Securities LLC acquired a new position in shares of ZIOPHARM Oncology in the fourth quarter valued at approximately $46,000. Allred Capital Management LLC acquired a new position in shares of ZIOPHARM Oncology in the fourth quarter valued at approximately $40,000. Finally, Rhumbline Advisers raised its position in shares of ZIOPHARM Oncology by 46.5% in the fourth quarter. Rhumbline Advisers now owns 175,080 shares of the biotechnology company’s stock valued at $327,000 after buying an additional 55,579 shares during the last quarter. 38.07% of the stock is owned by hedge funds and other institutional investors.
NASDAQ:ZIOP opened at $3.51 on Friday. The company has a market capitalization of $563.96 million, a PE ratio of -7.31 and a beta of 2.59. ZIOPHARM Oncology Inc. has a 1-year low of $1.56 and a 1-year high of $5.00.
A number of equities analysts have recently weighed in on ZIOP shares. BidaskClub raised shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating in a research report on Wednesday, November 28th. Raymond James raised shares of ZIOPHARM Oncology from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a research report on Thursday, November 15th. Finally, Zacks Investment Research raised shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $3.75 price objective for the company in a research report on Friday, December 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $4.92.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
Featured Story: Bollinger Bands
Want to see what other hedge funds are holding ZIOP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZIOPHARM Oncology Inc. (NASDAQ:ZIOP).
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.